Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Subscribe To Our Newsletter & Stay Updated
